Why the Paradigm (ASX:PAR) share price has rocketed 8% higher today

Paradigm Biopharmaceuticals Ltd (ASX: PAR) updated the market today on its phase III trial and product registration in Europe.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) updated the market today on its phase III trial and product registration in Europe. The news shot the Paradigm share price 8.3% higher to $2.47 at the time of writing. In comparison, the All Ordinaries Index (ASX: XAO) is trading marginally higher today at 0.2% to 6,152 points.

Let's look at what Paradigm announced.

research with microscope

Source: Getty Images

European Medicines Agency meeting

Paradigm received positive feedback from a meeting with the European Medicines Agency (EMA) for its product Zilosul. The company is developing Zilosul to treat chronic knee pain resulting from osteoarthritis (OA). Today's regulatory milestone will provide a clear pathway for Zilosul registration in Europe.

The meeting with EMA covered key elements of Paradigm's phase III trials, pre-clinical and manufacturing processes. EMA agreed on the proposed adaptive clinical trial design, including the conduct of two global, multicentre and randomised studies. This will include moderate to severe patients who have failed to respond to non-steroidal anti-inflammatory drugs and paracetamol. Evaluation will be done through WOMAC pain and WOMAC function, and the use of a saline placebo arm. In addition, Paradigm confirmed that the trial would not include an active comparator.

The meeting is expected to support Paradigm's submission of a marketing authorisation application (MAA) in Europe targeting knee OA.

The company plans to submit the same phase III clinical trial protocol to the United States Food and Drug Administration (FDA). Paradigm hopes to receive similar feedback in its Type C meeting that will assist its IND and subsequent NDA submission. The company advised it will present its Type C briefing book to the FDA in the coming weeks.

What did management say?

Paradigm's chief medical officer, Dr Donna Skerrett, was upbeat about the feedback for Zilosul, saying:

Paradigm is very pleased with the valuable guidance received from the EMA which provides clear direction as we advance our Phase 3 registration program toward bringing Zilosul to market.

The company remains focused on further demonstrating, via our Phase 3 clinical trials, the potential for Zilosul to be a treatment for the huge population of people suffering with chronic knee pain as a result of OA. This is another step toward our aim to have the pivotal protocol acceptable in all major jurisdictions providing Paradigm with a clarified path to global approval of Zilosul should our clinical trials be successful.

About the Paradigm share price

The Paradigm share price reached an all-time high of $4.50 before the onset of COVID-19, falling more than 72% in March. However, the Paradigm share price has since recovered from its 52-week low of $1.08, up 127%.

No tickers found. You need to add tickers and save as draft before fetching disclosure

More on ASX Share Market News

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

Worried unemployed woman sits on white chair waiting for job interview
ASX Share Market News

ASX 200 volatile as unemployment rises to a 5-year high, dampening rate hike fears

The unemployment rate rose to 4.9% in October, the highest level since October 2021.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »

Smiling woman taking a video through a plane window with her phone.
Broker Notes

Qantas or Virgin shares. Which ASX airline has more upside?

Will either share take off soon?

Read more »

Sad man sitting at desk and grabbing his head as he looks at a laptop.
ASX Share Market News

5 things to watch on the ASX 200 on Thursday

Investors might want to load their PlayStations and avoid another potential red day on the market today.

Read more »

A young well-dressed couple at a luxury resort celebrate successful life choices.
Opinions

My 3 biggest ASX portfolio winners and the one I'm buying more of

These businesses have significant growth potential.

Read more »

A man rests his chin in his hands, pondering what is the answer?
ASX Share Market News

Think you know the ASX? Try guessing the top 20 ASX shares of the past 20 years

Alongside the familiar names sit a couple of surprising names whose massive gains were supercharged by where they started two…

Read more »

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »